FDA Charges Ranbaxy with Falsifying Data at India Plant

The U.S. FDA has charged Ranbaxy Laboratories (Gurgaon, India) with falsifying data and test results in approved and pending drug applications at the company’s Paonta Sahib, India facility. The agency says it has stopped reviewing new or pending drug approval applications from the plant, which has been under an FDA import alert since last September for deviating from U.S. cGMP (CW, Sept. 22, 2008, p. 4). Ranbaxy says it will co-operate with FDA. Woodcock: ‘Companies must provide truthful and accurate information.’ Applications that are affected...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers